Caffeine therapy for apnea of prematurity.
BACKGROUND
Methylxanthines reduce the frequency of apnea of prematurity and the need for mechanical ventilation during the first seven days of therapy. It is uncertain whether methylxanthines have other short- and long-term benefits or risks in infants with very low birth weight.


METHODS
We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed. We evaluated the short-term outcomes before the first discharge home.


RESULTS
Of 963 infants who were assigned to caffeine and who remained alive at a postmenstrual age of 36 weeks, 350 (36 percent) received supplemental oxygen, as did 447 of the 954 infants (47 percent) assigned to placebo (adjusted odds ratio, 0.63; 95 percent confidence interval, 0.52 to 0.76; P<0.001). Positive airway pressure was discontinued one week earlier in the infants assigned to caffeine (median postmenstrual age, 31.0 weeks; interquartile range, 29.4 to 33.0) than in the infants in the placebo group (median postmenstrual age, 32.0 weeks; interquartile range, 30.3 to 34.0; P<0.001). Caffeine reduced weight gain temporarily. The mean difference in weight gain between the group receiving caffeine and the group receiving placebo was greatest after two weeks (mean difference, -23 g; 95 percent confidence interval, -32 to -13; P<0.001). The rates of death, ultrasonographic signs of brain injury, and necrotizing enterocolitis did not differ significantly between the two groups.


CONCLUSIONS
Caffeine therapy for apnea of prematurity reduces the rate of bronchopulmonary dysplasia in infants with very low birth weight. (ClinicalTrials.gov number, NCT00182312.).
Schmidt
Barbara
B
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ont, Canada. schmidt@mcmaster.ca
Roberts
Robin S
RS
Davis
Peter
P
Doyle
Lex W
LW
Barrington
Keith J
KJ
Ohlsson
Arne
A
Solimano
Alfonso
A
Tin
Win
W
D001049:Apnea / Q000188:drug therapy* / Q000628:therapy; D001997:Bronchopulmonary Dysplasia / Q000517:prevention & control*; D002110:Caffeine / Q000494:pharmacology / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000494:pharmacology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D019102:Infant, Very Low Birth Weight; D016015:Logistic Models; D008297:Male; D010102:Oxygen Inhalation Therapy; D012121:Respiration, Artificial; D015430:Weight Gain / Q000187:drug effects
D000697:Central Nervous System Stimulants; D002110:Caffeine